Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.
Advertisement

Related Content

Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY
Actelion Punches Back Against Activist Shareholder
Biogen Idec Reports Strong Earnings Thanks to Robust Sales Of Flagship Products
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles
Genzyme, Icahn Call Off Proxy Fight With Compromise Agreement
Genzyme, Industry Analysts Relieved By Particulars In Draft Consent Decree
Hang On To Those Ex-U.S. Rights, Biotech Veterans Termeer And Mullen Advise Start-Ups
But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”
But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”

Topics

Advertisement
UsernamePublicRestriction

Register

PS070384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel